Over 80 companies are actively developing treatments for Non-Alcoholic Steatohepatitis (NASH), with Inventiva Pharma and Cirius Therapeutics leading with Phase III candidates lanifibranor and MSDC-0602K respectively.
HTD1801, a plant-derived berberine medication, demonstrated significant blood glucose control in type 2 diabetes patients, with the highest dose reducing HbA1c by 0.7% over 12 weeks.
HighTide Therapeutics presented Phase 2 data on HTD1801 at EASD 2024, demonstrating benefits in both Chinese and Western patients with type 2 diabetes mellitus (T2DM).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.